The European Medicines Agency's Committee for Medicinal Products for Human Use has recommended approval for AVT03, Alvotech's proposed biosimilar to Prolia and Xgeva. This positive opinion marks a significant regulatory milestone for the Icelandic biotech company, bringing the medication one step closer to European market availability. The recommendation covers both the 60 mg/mL pre-filled syringe formulation and the 70 mg/mL vial version of the denosumab biosimilar.

AVT03 functions as a human monoclonal antibody that targets the RANK ligand membrane protein, reducing osteoclast activity to decrease bone resorption. Prolia is indicated for treating osteoporosis in postmenopausal women and men at increased fracture risk, while Xgeva prevents bone complications in adults with advanced cancer that has spread to bone. The biosimilar approach aims to provide comparable therapeutic benefits while potentially increasing affordability and access.

Upon final approval by the European Commission, STADA Arzneimittel AG will market the biosimilar under the brand names Kefdensis for the 60 mg/mL formulation and Zvogra for the 70 mg/mL version. Dr. Reddy's Laboratories SA will offer corresponding products named Acvybra and Xbonzy. Both partners hold semi-exclusive commercial rights across Europe, including Switzerland and the United Kingdom.

Joseph McClellan, Alvotech's Chief Scientific and Technical Officer, stated that this development demonstrates how the company's specialized biosimilars platform enables broader access to affordable biologic medicines. The product remains under EMA regulatory review pending a final decision by the European Commission, which typically follows the CHMP's positive recommendation within several months.

TGS, the Oslo-based energy data provider, has been awarded a significant ocean bottom node (OBN) acquisition contract in the Gulf of Mexico, marking another strategic win in one of the company's core markets. The 4D monitor survey is scheduled to commence in the fourth quarter of 2025 and will span approximately four and a half months. This contract represents continued confidence in TGS's capabilities from the international oil company client, though the specific customer identity remains undisclosed.

The contract was notably absent from TGS's booked position disclosed in the company's second quarter 2025 presentation, indicating a recent acquisition for the seismic data specialist. The Gulf of Mexico remains a critical region for offshore energy production, and 4D seismic monitoring plays an essential role in optimizing reservoir management and production efficiency for major operators in the region.

Kristian Johansen, CEO of TGS, emphasized the significance of securing business from repeat customers, stating that the client values TGS's OBN technology and proven track record of project execution. "The client is confident we will deliver high-quality data and insights to optimize production from one of their highest producing facilities in the Gulf of Mexico," Johansen commented, highlighting the operational importance of the project for the customer's production optimization efforts.

TGS's expertise in OBN technology positions the company as a trusted partner for international oil companies seeking to maximize recovery from existing assets. The 4D seismic approach allows operators to monitor reservoir changes over time, providing critical data for production optimization decisions. This latest contract win reinforces TGS's strong position in the Gulf of Mexico market and demonstrates the ongoing demand for advanced seismic monitoring solutions in mature offshore basins.